Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
Pharma News
FDA Grants Priority Review: Finerenone for CKD in Type 1 Diabetes Care
The FDA has granted priority review to Bayer’s finerenone for chronic kidney disease in adults with type 1 diabetes based on positive FINE-ONE trial data.
FDA Grants Breakthrough Designation to TOBY's Urine-Based Alzheimer Test
TOBY Inc. secures FDA Breakthrough Device Designation for its non-invasive, urine-based Alzheimer's diagnostic test utilizing VOCs and machine learning.
Europe Approves AstraZeneca's Camizestrant After FDA Advisory Rejection
Europe’s CHMP recommends AstraZeneca’s camizestrant for ER+/HER2- advanced breast cancer with ESR1 mutations, following a recent FDA committee rejection.
Asthma Drug Montelukast Shows Promise Fighting Highly Aggressive Cancers
Preclinical studies from Northwestern Medicine reveal that the common asthma drug montelukast can help treat aggressive cancers by blocking CysLTR1.
KLN-1010 Multiple Myeloma Clinical Trial Begins Dosing Patients in US
The Phase 1 inMMyCAR trial has officially begun dosing US patients with relapsed or refractory multiple myeloma using the experimental therapy KLN-1010.
Oral Namodenoson for Pancreatic Cancer to Advance into Phase 2b Trial
Can-Fite Biopharma advances oral namodenoson (CF102) to a Phase 2b trial for advanced pancreatic cancer following highly encouraging early study results.
Merck's Sacituzumab Tirumotecan Bests Chemo in Endometrial Cancer Trial
Merck’s Phase 3 TroFuse-005 trial shows sac-TMT significantly outperforms standard chemotherapy in advanced endometrial cancer, improving survival rates.
Akari Therapeutics Reveals Breakthrough AKTX-101 Synergy in KRAS Cancers
Akari Therapeutics announces breakthrough preclinical data showing AKTX-101, a TROP2-targeting ADC, synergizes with KRAS inhibitors in pancreatic cancer.
Verdiva Bio Preclinical Obesity Drug Data Slated for ADA 86th Sessions
Verdiva Bio to present preclinical data for oral obesity drugs VRB-103 and VRB-104 at the American Diabetes Association 86th Scientific Sessions in June.
US FDA Approves AstraZeneca's Baxfendy for Uncontrolled Hypertension Care
The US FDA approved AstraZeneca’s Baxfendy, a first-in-class aldosterone synthase inhibitor, for adults with resistant and uncontrolled hypertension.
Risen Pharma Starts Phase 2 Trial of RP902 for Mild Cognitive Impairment
Risen Pharma announces a Phase 2 clinical trial in China for RP902, an oral small-molecule drug targeting Alzheimer's disease patients with the ApoE ε4 gene.
Osteosarcoma Drug FL118 Earns FDA Orphan & Rare Pediatric Disease Status
The FDA granted rare pediatric disease and orphan drug designations to FL118, a novel camptothecin derivative for osteosarcoma developed by Roswell Park.
13
14
15
16
17
18
19
20
21
